One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity

Bioorganic and Medicinal Chemistry Letters

Volumn 27, Issue 11, 2017, Pages 2502-2505

  Botta, Lorenzo ^a   Maccari, Giorgio ^b   Calandro, Pierpaolo ^b   Tiberi, Marika ^b   Brai, Annalaura ^b   Zamperini, Claudio ^b   Canducci, Filippo ^c   Chiariello, Mario ^d   Martí Centelles, Rosa ^e   Falomir, Eva ^e   Carda, Miguel ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d ISTITUTO TOSCANO TUMORI   (Italy)

^e UNIVERSITAT JAUME I   (Spain)

Author keywords

Burkitt's Lymphoma; c Myc; Cancer; HIV; hTERT

Indexed keywords

ANTIRETROVIRUS AGENT; CAFFEINE; CYTOTOXIC AGENT; MYC PROTEIN; PROPRANOLOL; RALTEGRAVIR; RESVERATROL; TELOMERASE REVERSE TRANSCRIPTASE; TESTOSTERONE; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APPARENT PERMEABILITY; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SCREENING; DRUG SOLUBILITY; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN NL4.3); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IN VITRO STUDY; LD50; LIVER MICROSOME; MCF-7 CELL LINE; METABOLIC STABILITY; NONHUMAN; SELECTIVITY INDEX; VIRUS REPLICATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM;

ANTI-RETROVIRAL AGENTS; CELL SURVIVAL; GENE EXPRESSION; HIV-1; HT29 CELLS; HUMANS; MCF-7 CELLS; MICROSOMES, LIVER; PROTO-ONCOGENE PROTEINS C-MYC; TELOMERASE;

EID: 85017389804     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2017.03.097     Document Type: Article

References (17)

1. 1 Boshoff, C., Weiss, R., Nat Rev Cancer 2 (2002), 373–382.
2. 2 Cobuccia, R.N., Lima, P.H., Carvalho de Souza, P., et al. Inf Pub Health 8 (2015), 1–10.
3. 3 Berretta, M., Cinelli, R., Martellotta, F., Spina, M., Vaccher, E., Tirelli, U., Oncogene 22 (2003), 6646–6659.
4. 4 Monzon, J.G., Dancey, J., Combination agents versus multitargeted agents– pros and cons. Morphy, J.R., Harris, C.J., (eds.) Designing Multi-Target Drugs, 2012, RSC Publishing, Cambridge, 155–181.
5. 5 Tiberi, M., Tintori, C., Ceresola, E.R., et al. Antimicrob Agents Chemother 58 (2014), 3043–3052.
6. 6 Anderluh, M., Jukic, M., Petric, R., Tetrahedron 65 (2009), 344–350.
7. 7 Rinaldi, M., Tintori, C., Franchi, L., et al. Chem Med Chem 6 (2011), 343–352.
8. 8 Radi, M., Botta, L., Casaluce, G., Bernardini, M., Botta, M., J Comb Chem 12 (2010), 200–205.
9. 9 Arden, N., Betenbaugh, M.J., Trends Biotechnol 22 (2004), 174–180.
10. 10 Nicot, Marcia Bellon Christophe, J Natl Cancer Inst 100 (2008), 98–108.
11. 11 Ahuja, R., Jamal, A., Nosrati, N., et al. Curr Sci 107 (2014), 768–785.
12. 12 Bustin, S.A., Benes, V., Garson, J.A., et al. Clin Chem 55 (2009), 611–622.
13. 13 Latil, A., Vidaud, D., Valéri, A., et al. Int J Cancer 89 (2000), 172–176.
14. 14 Avdeef, A., Curr Top Med Chem 1 (2001), 277–351.
15. 15 Radi, M., Dreassi, E., Brullo, C., et al. J Med Chem 54 (2011), 2610–2626.
16. 16 Koljonen, M., Rousu, K., Cierny, J., Kaukonen, A.M., Hirvonen, J., Eur J Pharm Biopharm 70 (2008), 531–538.
17. 17 Habel, M.E., Jung, D., Biochem Biophys Res Commun 341 (2006), 1309–1316.